Papers
3
Total Citations
493
H-Index
2
About
Katsuto Shinohara is a leading figure in prostate cancer research, whose work has fundamentally shaped how clinicians treat and measure outcomes for the disease. His primary research areas include comparative effectiveness of radical therapies, adaptive robotic brachytherapy, and patient selection for focal therapies like high-intensity focused ultrasound (HIFU). Shinohara’s most impactful contribution is his landmark 2012 study, which provided a comprehensive comparative analysis of prostate-specific antigen (PSA) free survival outcomes across low, intermediate, and high-risk patients treated with radical therapy. With 459 citations, this work established a critical benchmark for evaluating treatment effectiveness using PSA as the most sensitive tool. In the realm of medical robotics, Shinohara demonstrated groundbreaking innovation by developing an adaptive workflow for stereotactic robotic brachytherapy, integrating an MR-stealth robot (MRBot) with inverse planning in a closed-bore 3T MRI. This work, while technically specialized, paved the way for more precise, image-guided interventions. Most recently, his 2025 study on optimal patient selection for HIFU reflects his ongoing commitment to personalizing prostate cancer care, ensuring that emerging technologies are applied to the patients who will benefit most.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3